Cai‐cun Zhou

Cai‐cun Zhou's AcademicInfluence.com Rankings

Cai‐cun Zhou

Engineering

#4056

World Rank

#5219

Historical Rank

Biomedical Engineering

#232

World Rank

#239

Historical Rank

engineering Degrees

Cai‐cun Zhou

Philosophy

#5813

World Rank

#8719

Historical Rank

Logic

#3024

World Rank

#4117

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Cai‐cun Zhou's Degrees

PhD Biomedical Engineering University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Cai‐cun Zhou Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cai‐cun Zhou's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. (2011) (3660)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018) (2753)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019) (1742)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. (2014) (1696)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. (2015) (1298)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. (2019) (1165)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. (2012) (927)
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019) (836)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. (2015) (698)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. (2015) (555)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. (2010) (418)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy (2015) (413)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. (2018) (406)
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. (2013) (363)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients (2018) (303)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. (2015) (294)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (2021) (284)
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. (2013) (283)
Role of IL-2 in cancer immunotherapy (2016) (274)
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. (2010) (261)
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. (2015) (248)
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. (2012) (232)
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. (2009) (209)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019) (208)
Tumor neoantigens: from basic research to clinical applications (2019) (207)
PD‐L1 Expression in Lung Cancer (2016) (203)
Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China (2007) (189)
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival (2017) (189)
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes (2017) (169)
Combined Radiotherapy and Anti–PD‐L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer (2017) (164)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC (2017) (158)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC (2017) (158)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. (2020) (156)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer (2019) (154)
TIM-3, a promising target for cancer immunotherapy (2018) (150)
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. (2018) (149)
cGAS-STING, an important pathway in cancer immunotherapy (2020) (146)
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. (2014) (144)
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer (2021) (143)
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer (2016) (137)
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. (2017) (126)
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. (2019) (126)
Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer (2015) (124)
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials (2012) (119)
Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First‐Line EGFR‐TKIs (2018) (118)
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. (2015) (116)
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. (2012) (116)
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases (2016) (110)
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. (2019) (107)
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules (2015) (102)
Lung cancer molecular epidemiology in China: recent trends. (2014) (100)
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. (2013) (100)
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer (2017) (97)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. (2021) (94)
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians (2012) (93)
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. (2014) (90)
Lung cancer in never smokers-the East Asian experience. (2018) (89)
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). (2012) (89)
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer (2014) (86)
EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies (2019) (85)
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers (2018) (82)
Role of circulating-tumor DNA analysis in non-small cell lung cancer. (2015) (81)
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12). (2021) (81)
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. (2020) (81)
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer (2015) (81)
Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. (2015) (81)
Strategies to Improve Outcomes of Patients with EGRF‐Mutant Non–Small Cell Lung Cancer: Review of the Literature (2016) (79)
Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset (2019) (78)
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer (2016) (75)
Lung cancer in China: current and prospect (2020) (72)
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. (2017) (71)
Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients (2014) (70)
Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma (2016) (68)
MHC class II expression in lung cancer. (2017) (68)
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma (2019) (68)
Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis (2016) (67)
Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer (2010) (67)
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker (2020) (66)
Targeting ferroptosis for cancer therapy: exploring novel strategies from its mechanisms and role in cancers (2020) (66)
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis (2018) (63)
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy (2021) (61)
FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. (2015) (59)
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. (2014) (59)
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. (2019) (57)
Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer (2018) (57)
Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. (2014) (57)
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis (2015) (56)
Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma (2012) (55)
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). (2021) (54)
ERCC1 is not expressed in hepatocellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study. (2011) (54)
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. (2021) (54)
Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. (2010) (53)
MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type (2014) (52)
Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes (2020) (51)
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). (2016) (51)
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer (2015) (51)
KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer (2013) (50)
E-Cigarettes and Cancer Patients (2014) (50)
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma (2012) (50)
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non‐squamous Non–small‐cell Lung Cancer (2018) (50)
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy (2020) (50)
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes (2010) (49)
The cutting-edge progress of immune-checkpoint blockade in lung cancer (2020) (49)
Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma. (2015) (49)
The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis. (2015) (48)
Predicting malignancy in mediastinal lymph nodes by endobronchial ultrasound: A new ultrasound scoring system (2012) (48)
Long non-coding RNA UCA1 promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis. (2018) (48)
Early detection of lung cancer by using an autoantibody panel in Chinese population (2018) (48)
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes (2017) (47)
Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement (2016) (47)
Targeting BRAF mutations in non-small cell lung cancer. (2019) (46)
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events (2019) (45)
Prognostic value of PD‐L1 expression in combination with CD8+ TILs density in patients with surgically resected non‐small cell lung cancer (2017) (45)
Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. (2020) (45)
Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn? (2021) (45)
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer (2011) (44)
Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy (2011) (44)
Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer. (2015) (44)
[China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)]. (2016) (43)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. (2022) (43)
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. (2020) (43)
Epithelial phenotype as a predictive marker for response to EGFR‐TKIs in non‐small cell lung cancer patients with wild‐type EGFR (2014) (43)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial (2019) (43)
EBUS-TBNA Provides Highest RNA Yield for Multiple Biomarker Testing from Routinely Obtained Small Biopsies in Non-Small Cell Lung Cancer Patients - A Comparative Study of Three Different Minimal Invasive Sampling Methods (2013) (42)
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF (2019) (42)
Heterogeneity of PD‐L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma (2018) (42)
Establishment of patient-derived tumor spheroids for non-small cell lung cancer (2018) (41)
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial (2013) (41)
The past, present and future of immunotherapy against tumor. (2015) (40)
Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small‐Cell Lung Cancer: Where Do We Stand? (2018) (40)
Arbutin attenuates LPS-induced lung injury via Sirt1/ Nrf2/ NF-κBp65 pathway. (2019) (40)
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study (2020) (39)
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. (2012) (38)
Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway (2020) (38)
Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations (2017) (38)
Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation (2017) (38)
Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial (2021) (38)
Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis (2016) (37)
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? (2014) (37)
First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease (2019) (37)
Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer (2010) (37)
Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. (2015) (36)
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. (2018) (36)
Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules. (2017) (35)
Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. (2019) (35)
Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer (2017) (35)
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer (2013) (35)
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer (2019) (35)
FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) (2008) (35)
Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy (2012) (34)
Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report (2016) (34)
MiR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells. (2016) (34)
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. (2019) (34)
High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients (2010) (34)
EML4–ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non–Small-Cell Lung Cancer (2015) (33)
Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804) (2015) (33)
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. (2018) (33)
Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer (2017) (32)
A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer (2015) (32)
Dynamic volume perfusion CT in patients with lung cancer: baseline perfusion characteristics of different histological subtypes. (2013) (32)
Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non‐small‐cell lung cancer (2015) (32)
A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. (2013) (31)
Protective effects of hesperetin on lipopolysaccharide‐induced acute lung injury by targeting MD2 (2019) (31)
Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer (2015) (31)
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design (2018) (31)
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers (2018) (31)
The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis. (2016) (30)
Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. (2020) (30)
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer (2015) (30)
Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2011) (30)
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC (2018) (30)
β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells. (2014) (30)
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. (2019) (29)
Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. (2013) (28)
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer (2020) (27)
RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studies. (2011) (27)
EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases (2018) (27)
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (27)
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. (2014) (27)
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. (2019) (27)
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. (2019) (27)
Rapid Detection of Epidermal Growth Factor Receptor Mutations in Non‐Small Cell Lung Cancer Using Real‐Time Polymerase Chain Reaction with TaqMan‐MGB Probes (2006) (27)
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. (2019) (27)
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. (2013) (26)
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer (2016) (26)
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. (2013) (26)
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. (2019) (26)
Galectin-9 in non-small cell lung cancer. (2019) (25)
Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR‐mutant NSCLC: A Multicenter Study (2017) (25)
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival (2011) (24)
A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. (2012) (24)
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer (2020) (24)
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC (2017) (24)
Clinical efficacy of erlotinib in patients previously treated for advanced non‐small cell lung cancer (2009) (24)
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial (2021) (24)
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC). (2016) (24)
4 – Lung Cancer in Never-Smokers: A Different Disease (2018) (24)
Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK. (2019) (23)
Mutational landscape and evolutionary pattern of liver and brain metastasis in lung adenocarcinoma. (2020) (23)
Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients (2012) (23)
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). (2015) (23)
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. (2018) (23)
Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (SAiL) Study (2011) (23)
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. (2019) (23)
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples12 (2014) (22)
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer (2020) (22)
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) (2017) (22)
Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy (2015) (22)
Prophylactic Cranial Irradiation May Impose a Detrimental Effect on Overall Survival of Patients with Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis (2014) (22)
Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer. (2018) (22)
Alterations of DNA damage repair in cancer: from mechanisms to applications (2020) (22)
Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer (2015) (22)
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China (2016) (21)
Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. (2019) (21)
Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. (2017) (21)
Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines (2013) (20)
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC (2021) (20)
PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201) (2017) (20)
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma (2016) (20)
Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy (2017) (20)
[China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)]. (2017) (20)
Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure (2019) (20)
China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version) (2017) (20)
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs (2018) (20)
Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018) (19)
Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in non‐small cell lung cancer (2009) (19)
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer (2017) (19)
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial (2018) (19)
Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. (2017) (19)
BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer (2011) (18)
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial (2022) (18)
Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study (2015) (18)
Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules. (2018) (18)
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. (2017) (18)
Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway (2015) (18)
sLAG-3 in non-small-cell lung cancer patients’ serum (2018) (18)
Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation. (2019) (17)
Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy. (2017) (17)
Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer (2019) (17)
LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC) (2020) (17)
Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases (2017) (17)
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. (2021) (17)
Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation. (2019) (17)
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. (2015) (16)
Long non-coding RNA UCA 1 induces non-T 790 M acquired resistance to EGFR-TKIs by activating the AKT / mTOR pathway in EGFR-mutant non-small cell lung cancer (2015) (16)
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure (2020) (16)
Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma (2020) (16)
Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer (2020) (16)
The tumor suppressor p53 regulates autophagosomal and lysosomal biogenesis in lung cancer cells by targeting transcription factor EB. (2017) (16)
Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. (2019) (16)
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn? (2021) (16)
LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations. (2013) (16)
Endobronchial ultrasound‐guided transbronchial needle aspiration for diagnosing mediastinal lymphadenectasis: a cohort study from a single center (2017) (16)
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China (2021) (16)
[Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer]. (2007) (16)
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). (2014) (15)
Serum Levels of the Cancer-Testis Antigen POTEE and Its Clinical Significance in Non-Small-Cell Lung Cancer (2015) (15)
Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review (2019) (15)
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy. (2012) (15)
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer1 (2017) (15)
Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer. (2020) (15)
Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors (2019) (15)
Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer Patients Treated With First‐Line EGFR Tyrosine Kinase Inhibitors (2019) (15)
Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1 (2012) (15)
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. (2017) (14)
Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer (2020) (14)
The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. (2017) (14)
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer (2017) (14)
Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer (2012) (13)
Slowing the Titanic: China's Epic Struggle with Tobacco (2016) (13)
Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo. (2005) (13)
Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. (2018) (13)
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study (2015) (13)
Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients. (2017) (13)
HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. (2020) (13)
Dual integrin αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance Imaging (2018) (13)
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases (2020) (13)
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). (2016) (13)
MA04.03 Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC (2017) (13)
SPOP promotes FADD degradation and inhibits NF-κB activity in non-small cell lung cancer. (2018) (13)
Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients (2020) (13)
High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients. (2015) (13)
Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. (2021) (12)
Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy (2022) (12)
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. (2020) (12)
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. (2012) (12)
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next. (2019) (12)
[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)]. (2014) (12)
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers (2014) (12)
[Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)]. (2021) (12)
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. (2021) (12)
A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients. (2018) (12)
Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer (2020) (12)
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. (2019) (12)
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial. (2020) (12)
Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. (2016) (11)
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small‐cell Lung Cancer on Progression‐free and Overall Survival (2017) (11)
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC. (2014) (11)
Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer. (2014) (11)
Serum cytokine levels in patients with advanced non‐small cell lung cancer: correlation with clinical outcome of erlotinib treatment (2013) (11)
Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. (2017) (11)
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules (2017) (11)
Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance (2021) (11)
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)]. (2016) (11)
A Case Report of Chemo-sensitive Intimal Pulmonary Artery Sarcoma (2013) (11)
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. (2018) (10)
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. (2019) (10)
Mosquito coil exposure associated with small cell lung cancer: A report of three cases (2015) (10)
FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III (2021) (10)
OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer (2017) (10)
The changing diagnostic pathway for lung cancer patients in Shanghai, China. (2017) (10)
A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis. (2020) (10)
Effect of nicotine dependence on quality of life and sleep quality in patients with lung cancer who continue to smoke after diagnosis. (2018) (10)
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)]. (2015) (9)
Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review (2018) (9)
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer (2020) (9)
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) (2022) (9)
The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis (2021) (9)
CD137, an attractive candidate for the immunotherapy of lung cancer (2020) (9)
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations (2021) (9)
Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC (2021) (9)
Non‐small cell lung cancer in China (2022) (9)
Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy (2021) (9)
Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (2020) (8)
Toxicity of tumor immune checkpoint inhibitors-more attention should be paid. (2019) (8)
The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes (2017) (8)
Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC. (2017) (8)
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (8)
Impact of Clinicopathologic Features on the Efficacy of PD‐1/PD‐L1 Inhibitors in Patients With Previously Treated Non–small‐cell Lung Cancer (2017) (8)
DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer (2021) (8)
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Study (8)
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC (2021) (8)
Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment (2019) (8)
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer (2020) (8)
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations (2021) (8)
The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy (2013) (8)
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. (2020) (8)
[Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice]. (2006) (8)
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations (2020) (7)
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. (2015) (7)
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer (2021) (7)
Effects of Collagen IV on Cisplatin-Induced Apoptosis of Non-Small Cell Lung Cancer Cells (2007) (7)
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough (2015) (7)
Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion (2020) (7)
Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. (2012) (7)
P3.02b-096 Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results: Topic: EGFR RES (2017) (7)
CD39: the potential target in small cell lung cancer (2020) (7)
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine (2014) (7)
[Relationship between polymorphisms of DNA repair gene ERCC1 and susceptibility to lung cancer.]. (2008) (7)
Adenovirus-mediated inhibitor kappaB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. (2008) (7)
Folate Receptor-Positive Circulating tumor cell detected by LT-PCR based method as a diagnostic biomarker for non-small cell lung cancer. (2015) (7)
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung (2018) (7)
Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies (2017) (7)
miR-512-5 p induces apoptosis and inhibits glycolysis by targeting p 21 in non-small cell lung cancer cells (2015) (7)
Immunotherapy of EGFR-positive tumor based on recombinant EGFR phage vaccine (2006) (7)
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review (2021) (7)
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer (2020) (6)
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs]. (2008) (6)
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study (2021) (6)
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer (2021) (6)
Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19 (2020) (6)
Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China (2015) (6)
High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer (2019) (6)
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. (2018) (6)
A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. (2017) (6)
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
Coexistence of Three Variants Involving Two Different Fusion Partners of ROS1 Including a Novel Variant of ROS1 Fusions in Lung Adenocarcinoma: A Case Report (2014) (6)
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors (2020) (6)
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. (2018) (5)
Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation. (2018) (5)
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC). (2014) (5)
The efficacy and complications of computed tomography guided microwave ablation in lung cancer. (2020) (5)
[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]. (2015) (5)
PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases (2020) (5)
Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. (2022) (5)
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma (2021) (5)
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial (2022) (5)
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. (2019) (5)
Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study (2018) (5)
Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. (2019) (5)
Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer. (2014) (5)
Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse (2021) (5)
[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes]. (2007) (5)
Comparison among different presentations of venous thromboembolism because of lung cancer (2019) (5)
Prognostic factors for survival in a Chinese population presenting with advanced non‐small cell lung cancer with an emphasis on smoking status: A regional, single‐institution, retrospective analysis of 4552 patients (2012) (5)
Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer (2019) (5)
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. (2010) (5)
Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients (2017) (5)
Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review (2020) (5)
Analyses of prognostic factors in cases of non-small cell lung cancer with multiple brain metastases (2016) (5)
Prognostic value of cyclooxygenase‐2 gene polymorphisms in advanced non‐small cell lung cancer patients treated with first‐line platinum‐based chemotherapy (2016) (5)
The association between polymorphisms in the DNA nucleotide excision repair genes and RRM1 gene and lung cancer risk (2012) (5)
Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer? (2019) (5)
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC (2021) (5)
A meta-analysis of comparing EGFR-TKI with chemotherapy as the second-line treatment of NSCLC patients with wild-type EGFR. (2013) (5)
Predictive and prognostic effect of CD 133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer (2015) (4)
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer]. (2008) (4)
Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment (2020) (4)
Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse (2022) (4)
Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). (2013) (4)
Treatment of spine metastases in cancer: a review (2019) (4)
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint. (2020) (4)
[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer]. (2013) (4)
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST. (2021) (4)
[Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib]. (2010) (4)
Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type small-cell lung cancer (2021) (4)
Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study (2018) (4)
[Blood-based Tumor Markers in Lung Cancer]. (2015) (4)
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma (2021) (4)
International consensus on severe lung cancer—the first edition (2021) (4)
Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer. (2014) (4)
Immunotherapy as a treatment for small cell lung cancer: a case report and brief review (2020) (4)
Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma (2021) (4)
Magnetic resonance imaging contrast agent: cRGD-ferric oxide nanometer particle and its role in the diagnosis of tumor. (2011) (4)
Something in need is something indeed. (2012) (4)
Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma. (2016) (4)
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma (2021) (4)
[Clinical characteristics and diagnosis of pulmonary mucosa-associated lymphoid tissue-derived (MALT) lymphoma: a retrospective analysis of 29 cases]. (2012) (4)
The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database. (2021) (4)
Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases (2016) (4)
Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug. (2015) (4)
Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation? (2020) (4)
Association Between Nicotine-dependent Gene Polymorphism and Smoking Cessation in Patients With Lung Cancer. (2020) (4)
The anti-tumor effects of lung cancer-targeting long-circulating paclitaxel-containing liposomes (2011) (3)
Mechanisms of Progression and Heterogeneity in Multiple Nodules of Lung Adenocarcinoma (2021) (3)
PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials (2022) (3)
Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer (2019) (3)
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines (2018) (3)
Efficacy of third‐generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non‐small‐cell lung cancer (2013) (3)
[The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro]. (2013) (3)
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). (2015) (3)
LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients. (2016) (3)
Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study. (2022) (3)
[Relationship between single nucleotide polymorphism of the equilibrative nucleoside transporter ENT3 and susceptibility to lung cancer]. (2010) (3)
Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial. (2022) (3)
Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. (2021) (3)
An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC) (2021) (3)
Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients (2014) (3)
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small cell lung cancer. (2015) (3)
From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. (2016) (3)
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel (2017) (3)
Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. (2019) (3)
Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. (2012) (3)
Value of heart rate recovery in female patients with pulmonary arterial hypertension due to systemic lupus erythematosus (2019) (3)
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases (2020) (3)
Matrix Analysis of Clinical Characteristics and Dynamic Observation of Immunological Features in 90 Cases of COVID-19 (2020) (3)
A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study (2021) (3)
Tumor autoantibodies (TAAs) panel can improve the accuracy of early diagnosis in lung cancer presenting with ground-glass nodules (GGNs) in Chinese population (2018) (3)
Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). (2014) (3)
Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. (2022) (3)
P47.13 Galectin-9, A Novel Prognostic Factor in Small Cell Lung Cancer (2021) (2)
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma (2019) (2)
Precision Medicine in Lung Cancer (2016) (2)
Risk factors for nicotine dependence in Chinese patients with lung cancer (2018) (2)
MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC (2017) (2)
[Relationship between mutations of epidermal growth factor receptor in the plasma and pleural effusion and responses to gefitinib in advanced pretreated non-small cell lung cancer]. (2007) (2)
CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. (2021) (2)
Detection of epidermal growth factor receptor mutations in small specimens of non-small cell lung cancer by amplification refractory mutation system (2012) (2)
The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review (2021) (2)
The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer. (2021) (2)
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection (2021) (2)
Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion (2021) (2)
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer (2021) (2)
Expert consensus on perioperative treatment for non-small cell lung cancer (2022) (2)
[Clinical characteristics and prognosis analysis of pulmonary carcinosarcoma (a report of 48 cases)]. (2007) (2)
Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention (2020) (2)
Relationship between DNA repair gene MMS19 single nucleotide polymorphisms and histology of non-small cell lung cancer (2011) (2)
Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies. (2019) (2)
Final safety and efficacy data for Asian patients (pts) in the MO19390 (SAiL) trial: First-line bevacizumab (Bv) plus chemotherapy in advanced or recurrent non-small cell lung cancer (NSCLC). (2010) (2)
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy (2022) (2)
Expression of Collagen IV, Fibronectin, Laminin in Non-small Cell Lung Cancer and Its Correlation with Chemosensitivities and Apoptosis (2006) (2)
Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial (2021) (2)
[Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines]. (2013) (2)
Immunotherapy in non-small cell lung cancer: advancements and challenges (2021) (2)
[Research progress of targeted therapy in non-small cell lung cancer brain metastases]. (2014) (2)
Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population. (2018) (2)
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. (2015) (2)
Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial. (2018) (2)
Survival without common toxicity criteria grade 3/4 toxicity following second‐line treatment with pemetrexed for nonsquamous non‐small cell lung cancer in Chinese patients (2013) (2)
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC). (2022) (2)
Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction. (2020) (2)
Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC) (2021) (2)
Validation of autoantibody panel for early detection of lung cancer in Chinese population. (2015) (2)
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort (2021) (2)
Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) (2014) (2)
Chemotherapy of lung cancer: A global perspective of the role of ifosfamide. (2012) (2)
PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology (2016) (2)
Pseudo-progression in a patient with lung adenocarcinoma and ALK fusion who responded to crizotinib (2016) (1)
Chinese expert consensus on diagnosis and treatment of radiation pneumonitis (2022) (1)
The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells (2014) (1)
Association of epithelial to mesenchymal transition with efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild type. (2012) (1)
Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution (2022) (1)
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD. (2022) (1)
Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing (2022) (1)
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (2009) (1)
[Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. (2011) (1)
Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial (2022) (1)
3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes (2015) (1)
P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: IT (2016) (1)
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures]. (2012) (1)
[Treatment of patients with ALK gene rearranged non-small cell lung cancer  after resistance to crizotinib]. (2015) (1)
[Relationship between ERCC1 expression and efficacy of neoadjuvant chemotherapy in the patients with non-small-cell lung cancer.]. (2008) (1)
P-143 Epidermal growth factor receptor mutations in Chinese patients with non-small cell lung cancer (2005) (1)
Paclitaxel (PTX) dose individualization by exposure optimization in Chinese patients with advanced non small-cell lung cancer (NSCLC) receiving first-line paclitaxel-carboplatin (PC) chemotherapy. (2015) (1)
A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer (2020) (1)
Influence of comorbidity on the choice of treatment and survival of elderly patients with advanced non-small cell lung cancer (2008) (1)
Screening of NSCLC samples from Chinese lung cancer patients for activating rearrangements of the ALK, RET, and ROS1 genes. (2013) (1)
[Treatment of patients with ALK gene rearranged non-small cell lung cancer after resistance to crizotinib]. (2015) (1)
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China (2022) (1)
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial (2022) (1)
[Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer]. (2007) (1)
Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma (2012) (1)
P2.01-121 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma (2018) (1)
Intratumoral heterogeneity and EGFR-TKIs resistance (2016) (1)
Abstract CT083: Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial (2020) (1)
Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. (2019) (1)
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration (2021) (1)
Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer (2008) (1)
Abstract 2247: A multicenter clinical trial of lung cancer circulating tumor cell assay with the largest sample size (1210 cases) in China (2016) (1)
Association of EGFR exon 19 deletion and miRNA expression in lung adenocarcinomas. (2014) (1)
Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer (2014) (1)
Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody (2023) (1)
Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report. (2010) (1)
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC). (2022) (1)
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) (2022) (1)
First-line therapy of advanced non-small cell lung cancer with activating EGFR mutations (2012) (1)
Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs (2018) (1)
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen. (2021) (1)
Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer. (2014) (1)
P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer: Topic: Targeted Therapy (2017) (1)
Icotinib versus gefi tinib in previously treated advanced non-small-cell lung cancer ( ICOGEN ) : a randomised , double-blind phase 3 non-inferiority trial (2013) (1)
Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer (2021) (1)
Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy (2022) (1)
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer (2022) (1)
[The salvage regimen for patients with advanced non-small cell lung cancer who failed prior chemotherapy: once-daily single oral agent Iressa]. (2004) (1)
P2-327: First-line chemotherapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC) (2007) (1)
MHC class II in lung cancer (2016) (1)
Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation (2021) (1)
The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC). (2022) (1)
A phase 1b study of famitinib plus docetaxel as 2nd line setting in patients with metastatic non-squamous non-small cell lung cancer and EGFR wild type. (2016) (1)
[Relationship of cytokine level with cancer cachexia and therapeutic effects of indomethacin for cancer cachexia]. (2004) (1)
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501). (2016) (1)
Necitumumab for patients with non-squamous NSCLC: uninspiring results. (2015) (1)
Lung cancer: continuous progress in diagnosis and treatment. (2021) (1)
Abstract CT555: Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study (2022) (1)
P3.02c-049 Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer: Topic: IT (2017) (1)
Effect of genomic and transcriptional alterations in first-line chemotherapy on subsequent immunotherapy in non-small cell lung cancer (NSCLC) patients. (2020) (1)
Efficacy of pemetrexed in a patient with brain metastases during crizotinib treatment. (2015) (1)
Preliminary study of immunology mechanism of erlotinib-induced skin rash (2011) (1)
A novel lanthanide-based NIR-II nanoprobe for lung squamous cell carcinoma identification. (2021) (1)
Efficacy-predictive biomarkers of anti-PD-1/PD-L1 immunotherapy for non-small cell lung cancer (2016) (1)
P1.01-10 Impact of Anti-COPD Support Treatment in Advanced NSCLC Patients with COPD Undergoing Chemotherapy as First-Line Treatment (2019) (0)
Development and Validation of a Pathomic Biomarker for Immunotherapy Response via Confounder-Aware Representation Learning (2022) (0)
P2-325: Chemotherapy in elderly (Over 75 years old)lung cancer patients: a retrospective analysis (2007) (0)
HER-2 mutations in Chinese lung adenocarcinoma patients with negative EGFR mutations. (2015) (0)
Influences of over-expression of VEGF-C and its inhibition on biological characteristics of NCI-H446 human small-cell lung cancer cells (2012) (0)
Research progress of pre-apoptotic protein him in tumor (2009) (0)
PUB007 Novel TKIs in Non-Small Cell Lung Cancer (2017) (0)
Notch Mutations as a Novel Biomarker for Immunotherapy. (2023) (0)
Molecular analysis of cell-free DNA to identify distinct molecular mutational burden and its effect on first-line chemotherapy in patients with NSCLC from a phase III trial. (2017) (0)
Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis (2022) (0)
[An anti-tumor research of recombinant phage vaccine expressed xenogenic EGFR]. (2005) (0)
HOTAIR to induce EGFR-TKIs resistance in non-small cell lung cancer via epithelial-mesenchymal transition. (2015) (0)
P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer: Topic: EGFR Clinical (2017) (0)
Reply to J. Jürgens et al. (2016) (0)
P1.14-40 EGFR-TKIs May Sensitize Radiation Lung Damage in Stereotactic Body Radiotherapy Based on Intensity Analyzing (2019) (0)
P3.02b-091 Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation: Topic: EGFR Clinical (2017) (0)
SC05.03 Novel Tyrosine Kinase Inhibitors in Lung Cancer (2017) (0)
Analysis of the clinical characteristics between cavitating squamous cell lung carcinoma and non-cavitating squamous cell lung carcinoma (2007) (0)
P3.02b-104 Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure (2017) (0)
[Gefitinib in the treatment of refractory non-small cell lung cancer]. (2007) (0)
P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients: Topic: EGFR Clinical (2017) (0)
Expressionn of ERCC1 and its influence on efficacy of induction chemotherapy in non-small cell lung cancer (NSCLC) (2007) (0)
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers (2018) (0)
Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity (2021) (0)
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study (2022) (0)
microRNA expression profiles in acquired gefitinib-resistant human lung adenocarcinoma cell line PC9/AB2 vs its parental cell line PC9 (2012) (0)
Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients (2016) (0)
SY10-1 The emerging role of cell-free DNA as a biomarker for cancer immunotherapy (2021) (0)
OTT_A_214211 7347..7353 (2019) (0)
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. (2023) (0)
Impact of Whole Brain Radiotherapy on Leptomeningeal Metastasis from Non-Small Cell Lung Cancer in Targeted Therapy Era (2020) (0)
P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers (2017) (0)
Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor (2022) (0)
Individual chemotherapy of non-small cell lung cancer (2010) (0)
CNSC-38. EGFR AMPLIFICATION IS A PUTATIVE RESISTANCE MECHANISM FOR NSCLC-LM PATIENTS WITH TKI THERAPY AND IS ASSOCIATED WITH POOR OUTCOME (2022) (0)
Abstract 2252: Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in non-small cell lung cancer patients receiving first-line platinum-based chemotherapy (2016) (0)
CLO22-089: BC200 Mediates Immune Escape in NSCLC by Affecting Tumor-Immune Microenvironment (2022) (0)
Abstract CT553: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): Subanalysis from the RATIONALE-303 phase 3 randomized clinical study (2022) (0)
P2-326: Extracellular matrix expression in non-small cell lung cancer and the relationship with neo-adjuvant chemotherapy (2007) (0)
P60.03 Transcriptome and Genome Profiles of Metastatic Lung Cancers Highlighted Predictive Power of Infection-Related Model in Metastasis (2021) (0)
A retrospective analysis of the ICOGEN clinical trial demonstrates the utility of VeriStrat to predict outcome in an all Chinese cohort treated with EGFR TKI. (2016) (0)
Evaluation of liquid biopsies for molecular profiling in patients (pts) with advanced non-small cell lung cancer (NSCLC): What happens after panel testing by next generation sequencing (NGS)? (2018) (0)
Continuing EGFR-TKI in combination with super-selected arterial infusion chemotherapy beyond RECIST PD for patients with advanced EGFR positive mutation non-small cell lung cancer. (2015) (0)
CNSC-04. CEREBROSPINAL FLUID-DERIVED CIRCULATING TUMOR DNA IS SUPERIOR TO PLASMA IN NSCLC PATIENTS WITH CNS PROGRESSION (2022) (0)
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design (2018) (0)
Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy. (2014) (0)
Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report (2016) (0)
Genopathomic Profiling Identifies Signatures for Immunotherapy Response of Lung Cancer Via Confounder-Aware Representation Learning (2022) (0)
Reply to association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma (2013) (0)
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer (2022) (0)
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply. (2020) (0)
[The value of detection of gene rearrangement of immunoglobulin heavy chain and immunohistochemistry in pulmonary mucosa-associated lymphoid tissue type lymphoma]. (2005) (0)
[Analysis of mutation feature at exon 19 of epidermal growth factor receptor gene in non-small cell lung cancer from Chinese patients]. (2008) (0)
Constitution of ALK fusion variants in East Asian lung adenocarcinoma (2016) (0)
Impact of Dissected Lymph Node Count on PD-1 Inhibitors Efficacy in Postoperative Recurred NSCLC: A Multi-Institutional Retrospective Study (2021) (0)
[Immunotherapeutic effect of recombinant EGFR phage vaccine on tumors]. (2006) (0)
First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations (2012) (0)
P-039 Effects of cyclooxygenase-2 antisense vector on sensitivity to cisplatin of human non-small cell lung cancer cells (2005) (0)
Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation (2023) (0)
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis (2022) (0)
[Molecular diagnostics and molecular prognosis in lung cancer.]. (2008) (0)
BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils (2022) (0)
Biomarkers in early diagnosis and screening of lung cancer (2017) (0)
A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma (2022) (0)
Cognitive functions before radiotherapy in pediatric patients with brain tumors (2019) (0)
Integrin β 1 participates in acquired resistance to gefitinib in non-small cell lung cancer: Integrin β 1 participates in acquired resistance to gefitinib in non-small cell lung cancer (2013) (0)
Research progress of mTOR signaling pathway and non-small cell lung cancer (2013) (0)
Diagnosis and Treatment Experience of 101 Patients with Advanced NSCLC Complicated with Chronic Obstructive Pulmonary Disease: P014 (2018) (0)
[Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer]. (2004) (0)
[Effect of inhibitor κB transfection on tumorigenesis of human lung cancer cell line H460]. (2005) (0)
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. (2023) (0)
The role of up-regulation of integrin β1 in resistance to gefitinib in non-small cell lung cancer (2011) (0)
Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer (2018) (0)
Predictive effects of RRM1, ERCC1, XRCC3, BRCA1 and EGFR genotyping or expression for clinical outcome of advanced NSCLC patients treated with cisplatin–based chemotherapy or gefitinib (2009) (0)
Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction. (2023) (0)
Progress on epidermal growth factor receptor tyrosine kinase inhibitor for treatment of advanced non-small cell lung cancer (2011) (0)
[Effects of cyclooxygenase-2 antisense vector on proliferation and sensitivity to cisplatin of H1299 cells]. (2005) (0)
Mutual antagonism of microRNA-21 and BIM protein in the reversal of multidrug resistance to EGFR-TKIs in lung adenocarcinoma cells (2015) (0)
Differential Organ-Specific Tumor Response to First-Line Immune Checkpoint Inhibitors Therapy in NSCLC (2022) (0)
Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020) 76-82]. (2021) (0)
Efficacy and Safety of High Dose Radiotherapy for the Treatment of Locally Advanced Rectal Cancer (2020) (0)
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma (2019) (0)
Advances in T cells-based immunotherapy for non-small cell lung cancer (2015) (0)
P2.01-111 Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma (2018) (0)
[Hydroxycamptothecine and ifosfamide as second-line therapy in non-small cell lung cancer after prior treatment with platinum-based regimens]. (2005) (0)
CNSC-01. THE GENE LANDSCAPE OF LUNG ADENOCARCINOMA PATIENTS WITH PROGRESSIVE DISEASE OF LEPTOMENINGE (2022) (0)
Computational recognition of LncRNA signatures in tumor-associated neutrophils could have implications for immunotherapy and prognostic outcome of non-small cell lung cancer (2022) (0)
Conventionally fractionated radiation and anti-PD-L1 treatment to relieve radiation resistance via regulation proliferation pathway and immunity system. (2016) (0)
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China (2016) (0)
Clinical research on prediction marker of efficacy in advanced non-small cell lung cancer (2010) (0)
Future perspectives of precision medicine for NSCLC. (2018) (0)
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study (2023) (0)
An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients. (2017) (0)
EP1.01-08 Efficacy of Osimertinib in Patients of Advanced Non-Small Cell Lung Cancer with Brain Metastasis: A Retrospective Analysis (2019) (0)
P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer (2007) (0)
P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK (2017) (0)
PUB106 Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients (2017) (0)
[c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro]. (2013) (0)
Recent advances in immunotherapy for lung cancer (2023) (0)
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial (2022) (0)
CMAR_A_302545 3981..3990 (2021) (0)
MA01.04 A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC (2021) (0)
The in vitro synergistic cytotoxic effects of inductive, concurrent and sequential cyclooxygenase-2 inhibitor with cisplatin against A549 cell line (2004) (0)
P-598 Oxaliplatin plus vinorelbine in advanced non-small cell lung cancer (2005) (0)
Advances in the management of elderly patients with advanced non-small cell lung cancer (2015) (0)
P47.07 Exploration of Aberrant Methylation Patterns in the Chemotherapy Insensitivity of Small Cell Lung Cancer (2021) (0)
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers (2018) (0)
A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer (2020) (0)
Clinical efficacy of pemetrexed in the treatment of non-small cell lung cancer with asymptomatic brain metastasis (2011) (0)
A Case Report of Chemo-sensitive Intimal Pulmonary Artery Sarcoma (2013) (0)
EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome (2022) (0)
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC (2022) (0)
Ef ﬁ cacy of Brigatinib in Patients With Advanced ALK -Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) (2022) (0)
[Maintenance therapy in advanced non-small cell lung cancer: controversy and consensus]. (2012) (0)
OTT_A_214231 7281..7288 (2019) (0)
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer (2013) (0)
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations (2023) (0)
Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer (2017) (0)
Osimertinib for EGFR T790M positive non-small cell lung cancer—making it happen, turning good idea into great results (2017) (0)
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia. (2020) (0)
Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning (2022) (0)
[Mutations in exon 19 of EGFR gene in non-small cell lung cancer from Chinese patients]. (2008) (0)
5th Asia Pacific Lung Cancer Conference (2013) (0)
Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer (2009) (0)
PS1-5 IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC (2022) (0)
PUB092 Efficacy of Crizotinib and Pemetrexed-Based Chemotherapy in Chinese NSCLC Patients with ROS1 Rearrangement (2017) (0)
Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing (2022) (0)
Abstract 5891: Plasma-based BDA-NGS test holds potential in circulating nucleic acid based oncogenic aberration detection (2020) (0)
A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease. (2023) (0)
Updated results of CameL-sq trial confirm benefit of camrelizumab (2022) (0)
PUB043 KIR 2D (L1, L3, L4, S4) and KIR 3DL1 Protein Expression in Non-small Cell Lung Cancer (2017) (0)
A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen. (2018) (0)
Circulating tumor cells and evaluation of targeted therapy effect in EGFR mutation/ALK translocation metastatic non-small cell lung cancer. (2015) (0)
Preliminary safety and efficacy of camrelizumab plus nab-paclitaxel and carboplatin as frontline setting in extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial. (2022) (0)
P3.02b-076 Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases: Topic: EGFR Clinical (2017) (0)
The largest sample size (2,200 cases) pooled analysis of LT-PCR achieving quantitative determination of folate receptor-positive CTCs for lung cancer in China. (2016) (0)
Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study (2022) (0)
Genomic characterization and outcome evaluation of kinome fusions in a large non-small cell lung cancer population. (2020) (0)
Association between variable number of tandem repeat polymorphism of thymidylate synthase gene and efficacy of pemetrexed in the treatment of advanced non-small cell lung cancer (2012) (0)
P2-156: Effects of collagen IV on cisplatin-induced apoptosis of non-small cell lung cancer cells (2007) (0)
A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC. (2016) (0)
Ef ﬁ cacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial (0)
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer (2022) (0)
Clinical significance of hyperpigmentation due to pemetrexed treatment in advanced nonsquamous non-small cell lung cancer in China. (2012) (0)
P1.07-031 Clinical Evaluation of Folate Receptor-Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer: Topic: Molecular Changes (2017) (0)
Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial. (2023) (0)
Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303 (2022) (0)
Dynamic monitoring and predictive value of circulating tumor cells in EGFR mutant advanced NSCLC patients treated with first-line EGFR-TKIs. (2018) (0)
Abstract CT554: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study (2022) (0)
[The role of nitric oxide in the cytotoxic effect of macrophages]. (2003) (0)
[Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer]. (2012) (0)
[Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC]. (2014) (0)
Updates on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer (2008) (0)
P2-155: STI-571 inhibits the growth of non-small cell lung cancer cell and intensifies the cisplatin effect in vitro (2007) (0)
Conference Scene: 5th Asia Pacific Lung Cancer Conference (2013) (0)
Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis (2021) (0)
Quantitative test of mutant EGFR and its effect on efficacy of EGFR TKI in advanced NSCLC. (2013) (0)
P2.12-22 Risk Factors for BM Incidence in SCLC: A Predictive Model for SCLC Patients on Brain Metastasis (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cai‐cun Zhou?

Cai‐cun Zhou is affiliated with the following schools:

University of Sydney
Kansai Medical University
Tongji University

Cai‐cun Zhou's Academic­Influence.com Rankings

Cai‐cun Zhou's Degrees

Why Is Cai‐cun Zhou Influential?

Cai‐cun Zhou's Published Works

Published Works

What Schools Are Affiliated With Cai‐cun Zhou?

Cai‐cun Zhou's AcademicInfluence.com Rankings